Physician profile
Michael Loeffler
NPI 1730219718
$1,791.39
in general payments reported to CMS, 2019-2025
25 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $198 · 2021: $361 · 2022: $451 · 2023: $143 · 2024: $380 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $648 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.20 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $215.46 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $204.95 | 2022-2025 | Vyzulta, Miebo |
| Abbvie INC. | $191.91 | 2022-2025 | |
| Alcon Vision LLC | $174.25 | 2019-2024 | Rocklatan, Clareon, Hydrus Microstent |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $148.01 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $131.10 | 2022 | |
| Astellas Pharma US INC | $80.91 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $70.58 | 2021-2022 | |
| Rxsight INC | $61.38 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $60.60 | 2020 | |
| Horizon Therapeutics Plc | $59.76 | 2021-2022 | |
| Dompe US, INC. | $55.59 | 2021-2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $36.60 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $36.25 | 2024 | Xdemvy |
| Amgen INC. | $32.46 | 2024 | Tepezza |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $31.78 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $30.73 | 2022 | |
| Glaukos Corporation | $29.55 | 2024 | Ce-Marked Kxla System |
| Santen INC. | $27.71 | 2023 | Verkazia |
| Biotissue Holdings INC. | $25.83 | 2025 | |
| Akorn Operating Company LLC | $23.19 | 2021 | |
| Akorn, INC. | $21.33 | 2020 | |
| Eyevance Pharmaceuticals LLC | $16.08 | 2020 | |
| Shire North American Group INC | $13.70 | 2019 | |
| Thea Pharma INC. | $11.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Loeffler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.